[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100523228":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":109,"collaborators":11,"id":113,"slug":11,"hasResults":114,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":11,"eligibilityCriteria":118,"healthyVolunteers":114,"sex":119,"minAge":120,"maxAge":11,"enrollmentInfo":121,"targetDuration":11,"studyType":124,"phases":125,"briefSummary":127,"conditions":128,"keywords":135,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":148},{"fullName":5,"class":6},"Cedars-Sinai Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single Arm","EXPERIMENTAL",null,[13,14],"Procedure: Breast Surgery (BCS or mastectomy) with TAD\u002FSNB","Radiation: Adjuvant Radiation Therapy",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":11},"PROCEDURE","Breast Surgery (BCS or mastectomy) with TAD\u002FSNB","Breast surgery (BCS or mastectomy) with TAD\u002FSNB \\& Adjuvant Radiation therapy",[9],{"type":22,"name":23,"description":19,"armGroupLabels":24,"otherNames":11},"RADIATION","Adjuvant Radiation Therapy",[9],[26],{"name":27,"affiliation":5,"role":28},"Alice Chung, MD","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Clinical Trial Navigator","CONTACT","3104232133","GroupCancerTrialInformation@cshs.org",[36,76,94],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute","RECRUITING","Los Angeles","California","90048","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-118.24368,34.05223,{"lat":48,"lon":47},[51,54,57,59,61,63,64,66,68,70,72,74],{"name":52,"role":32,"phone":53,"phoneExt":11,"email":34},"Clinical Trial Recruitment Navigator","310-423-3713",{"name":55,"role":56,"phone":11,"phoneExt":11,"email":11},"Scott Karlan, MD","SUB_INVESTIGATOR",{"name":58,"role":56,"phone":11,"phoneExt":11,"email":11},"Armando Giuliano, MD",{"name":60,"role":56,"phone":11,"phoneExt":11,"email":11},"Catherine Dang, MD",{"name":62,"role":56,"phone":11,"phoneExt":11,"email":11},"Farin Amersi, MD",{"name":27,"role":28,"phone":11,"phoneExt":11,"email":11},{"name":65,"role":56,"phone":11,"phoneExt":11,"email":11},"Marissa Boyle, MD",{"name":67,"role":56,"phone":11,"phoneExt":11,"email":11},"Kjirsten Carlson, MD",{"name":69,"role":56,"phone":11,"phoneExt":11,"email":11},"Stephen Shiao, MD PhD",{"name":71,"role":56,"phone":11,"phoneExt":11,"email":11},"Julie Jang, MD",{"name":73,"role":56,"phone":11,"phoneExt":11,"email":11},"Michele Burnison, MD",{"name":75,"role":56,"phone":11,"phoneExt":11,"email":11},"Amin Mirhadi, MD",{"facility":77,"status":38,"city":78,"state":40,"zip":79,"country":42,"countryCode":43,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"CS Cancer at Huntington Cancer Center","Pasadena","91105",{"type":45,"coordinates":81},[82,83],-118.14452,34.14778,{"lat":83,"lon":82},[86,88,90,92],{"name":11,"role":32,"phone":87,"phoneExt":11,"email":11},"424-314-0177",{"name":89,"role":56,"phone":11,"phoneExt":11,"email":11},"Jeannie Shen, MD",{"name":91,"role":56,"phone":11,"phoneExt":11,"email":11},"Amy Polverini, MD",{"name":93,"role":56,"phone":11,"phoneExt":11,"email":11},"Alicia Terando, MD",{"facility":95,"status":38,"city":96,"state":40,"zip":97,"country":42,"countryCode":43,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"CS Cancer at Valley Oncology Medical Group","Tarzana","91356",{"type":45,"coordinates":99},[100,101],-118.55397,34.17334,{"lat":101,"lon":100},[104,107],{"name":105,"role":32,"phone":11,"phoneExt":11,"email":106},"Vanessa Vasco","Vanessa.Vasco@cshs.org",{"name":108,"role":56,"phone":11,"phoneExt":11,"email":11},"Lauren DeStefano, MD",{"type":110,"investigatorFullName":111,"investigatorTitle":112,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Alice Chung","Sponsor-Investigator","100523228",false,"NCT06092892","IIT2023-09-Chung-UpfrontTAD: Upfront TAD\u002FSNB in Patients With Breast Cancer With Nodal Metastases","IIT2023-09-Chung-UpfrontTAD: Upfront TAD\u002FSNB in Patients With Clinical T1-2N0 ER+ Her2- Breast Cancer With Ultrasound Detected Nodal Metastases","Inclusion Criteria:\n\n* Women age ≥ 45\n* Clinical T1-2N0 ER+ invasive breast cancer\n* US detected biopsy proven axillary nodal disease\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n\nExclusion Criteria:\n\n* Palpable nodes on physical exam\n* Her2+ or ER- invasive breast cancer\n* Extranodal extension \\> 3 mm on nodal biopsy\n* More than 2 suspicious nodes on preoperative imaging","FEMALE","45 Years",{"count":122,"type":123},45,"ESTIMATED","INTERVENTIONAL",[126],"PHASE2","The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+\u002FHer2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or mastectomy with TAD followed by adjuvant therapy. This is a prospective, single arm phase II clinical trial. Patients will be screened and enrolled per eligibility criteria. Patient, tumor, and treatment data will be documented.",[129,130,131,132,133,134],"Breast Cancer","Axillary Nodal Disease","Female Breast Cancer","Axilla; Breast","Mastectomy; Lymphedema","Tumor, Breast",[136,137,138],"T1-2N0 ER+ invasive","biopsy","upfront lumpectomy","2026-05-06",{"date":141,"type":142},"2026-05-11","ACTUAL",{"date":144,"type":142},"2024-04-07",{"date":146,"type":123},"2031-04",{"name":111,"class":6},3]